Benjamin Moran

Benjamin Moran

Auto-generated profile, based on publicly available information

Benjamin Moran

Department of Intensive Care, Gosford Hospital, Gosford, Australia; Department of Anaesthesia and Pain Medicine, Gosford Hospital, Gosford, Australia; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Anaesthesia and Intensive Care
Verified
Journal Article
Closed access
BMBenjamin L Moran
Benjamin L Moran
JMJohn A Myburgh
John A Myburgh
DSDavid A Scott
David A Scott
Opioids are a commonly administered analgesic medication in the intensive care unit, primarily to facilitate invasive mechanical ventilation. Consensus guidelines advocate for an opioid-first strategy for the management of acute pain in ventilated patients. As a result, these patients are potentially exposed to high opioid doses for prolonged periods, increasing the risk of adverse effects. Adverse effects relevant to these critically ill patients include delirium, intensive care unit–acquired infections, acute opioid tolerance, iatrogenic withdrawal syndrome, opioid-induced hyperalgesia, persistent opioid use, and chronic post–intensive care unit pain. Consequently, there is a challenge of optimising analgesia while minimising these adverse effects. This narrative review will discuss the characteristics of opioid use in the intensive care unit, outline the potential short-term and long-term adverse effects of opioid therapy in critically ill patients, and outline a multifaceted strategy for opioid minimisation.

2 September 2024 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
RLRyan Ruiyang Ling
Ryan Ruiyang Ling
MRMallikarjuna Ponnapa Reddy
Mallikarjuna Ponnapa Reddy
ASAshwin Subramaniam
Ashwin Subramaniam
BMBenjamin Moran
Benjamin Moran
KRKollengode Ramanathan
Kollengode Ramanathan
KSKiran Shekar
Kiran Shekar
Purpose Acute hypoxaemic respiratory failure (AHRF) is a common reason for intensive care unit (ICU) admission. However, patient characteristics, outcomes, and trends over time are unclear. We describe the epidemiology and outcomes of patients with AHRF over time. Methods In this binational, registry-based study from 2005 to 2022, we included all adults admitted to an Australian or New Zealand ICU with an arterial blood gas within the first 24 h of ICU stay. AHRF was defined as a partial pressure of oxygen/inspired oxygen ratio (PaO2/FiO2) ≤ 300. The primary outcome was adjusted in-hospital mortality, categorised based on PaO2/FiO2 (mild: 200–300, moderate: 100–200, and severe < 100, and non-linearly). We investigated how adjusted mortality evolved based on temporal trends (by year of admission), sex, age, admission diagnosis and the receipt of mechanical ventilation. Results Of 1,560,221 patients, 826,106 (52.9%) were admitted with or developed AHRF within the first 24 h of ICU stay. Of these 826,106 patients, 51.4% had mild, 39.3% had moderate, and 9.3% had severe AHRF. Compared to patients without AHRF (5.3%), patients with mild (8%), moderate (14.2%) and severe (29.9%) AHRF had higher in-hospital mortality rates. As PaO2/FiO2 ratio decreased, adjusted in-hospital mortality progressively increased, particularly below an inflection point at a PaO2/FiO2 ratio of 200. The adjusted in-hospital mortality for all patients decreased over time (13.3% in 2005 to 8.2% in 2022), and this trend was similar in patients with and without AHRF. Conclusion The healthcare burden due to AHRF may be larger than expected, and mortality rates remain high in severe AHRF. Although mortality has decreased over time, this may reflect improvements in ICU care in general, rather than specifically in AHRF. More research is required to earlier identify AHRF and stratify these patients at risk of deterioration early, and to validate our findings.

30 April 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
THTessa Hunt
Tessa Hunt
TPThomas Payne
Thomas Payne
JBJames M. Brophy
James M. Brophy
JIJoanne Irons
Joanne Irons
AWAndy Y. Wang
Andy Y. Wang
RSRobert D. Sanders
Robert D. Sanders

13 March 2025 in Critical Care and Resuscitation
Verified
Journal Article
Open access
MRMahesh Ramanan
Mahesh Ramanan
DRDorrilyn Rajbhandari
Dorrilyn Rajbhandari
CKCarolyn Koch
Carolyn Koch
YAYasmine Ali Abdelhamid
Yasmine Ali Abdelhamid
AAAntony George Attokaran
Antony George Attokaran
BVBalasubramanian Venkatesh
Balasubramanian Venkatesh
The optimal choice of fluid therapy for patients with diabetic ketoacidosis (DKA) is uncertain, though preliminary data suggest that buffered crystalloid solutions (Plasma-Lyte® 148) may offer some advantages over 0.9% saline. To describe the study protocol for the ‘Balanced Electrolyte Solution versus Saline Trial for Diabetic Ketoacidosis’ (BEST-DKA) trial. BEST-DKA is a Phase 3 cluster-crossover, blinded, pragmatic, randomised, controlled trial comparing the effects of saline or buffered crystalloid solution in patients with moderate to severe DKA treated in the emergency department and/or intensive care unit at twenty hospitals in Australia. Each hospital will be randomised to use either saline or buffered crystalloid solution for a period of 12 months before crossing over to the alternate fluid for the next 12 months. The blinded study fluid will be used for all resuscitation and maintenance purposes for included patients. This cluster-randomised, crossover randomised controlled trial (RCT) has been designed with the aim of enrolling a minimum of 400 patients, which will provide >91.4% power to detect a 2-day increase in the primary outcome, days alive and out of hospital to day 28, chosen with consumer representation. Secondary outcomes include quality of life and fatigue scores at day 28, intensive care unit and hospital lengths of stay, acute kidney injury, and time to resolution of DKA. All analyses will be conducted on an intention-to-treat basis. A prespecified statistical analysis plan will be developed prior to interim analysis. The BEST-DKA trial commenced enrolment in March 2024 and should generate results that will determine whether treatment with Plasma-Lyte® 148, compared with saline, results in increased days alive, and out of hospital to day 28 for patients with moderate or severe DKA.

30 August 2022 in Critical Care and Resuscitation
Verified
Journal Article
Open access
BMBenjamin L. Moran
Benjamin L. Moran
DSDavid A. Scott
David A. Scott
EHElizabeth Holliday
Elizabeth Holliday
SKSerena Knowles
Serena Knowles
MSManoj Saxena
Manoj Saxena
JMJohn A. Myburgh
John A. Myburgh
OBJECTIVE: To describe pain assessment and analgesic management practices in patients in intensive care units (ICUs) in Australia and New Zealand. DESIGN, SETTING AND PARTICIPANTS: Prospective, obs...

26 February 2026 in Critical Care Science
Verified
Journal Article
Open access
PDF file
MRMahesh Ramanan
Mahesh Ramanan
BMBenjamin Moran
Benjamin Moran
RLRyan Ruiyang Ling
Ryan Ruiyang Ling
ABAidan Burrell
Aidan Burrell
ASAshwin Subramaniam
Ashwin Subramaniam
KSKiran Shekar
Kiran Shekar
Objective To determine the optimal PaO2:FiO2 threshold in the first 24 hours of intensive care unit admission, and its associated discriminatory capacity, for prognostication of mortality among critically ill patients. Methods This bi-national registry included adult patients admitted to intensive care units in Australia and New Zealand from January-2018 to December-2022. The primary outcome […] ABSTRACT Objective To determine the optimal PaO2:FiO2 threshold in the first 24 hours of intensive care unit admission, and its associated discriminatory capacity, for prognostication of mortality among critically ill patients. Methods This bi-national registry included adult patients admitted to intensive care units in Australia and New Zealand from January-2018 to December-2022. The primary outcome […]